株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Breo Ellipta(ぜんそく):市場の予測と分析

Breo Ellipta (Asthma) - Forecast and Market Analysis to 2023

発行 GlobalData 商品コード 316075
出版日 ページ情報 英文 53 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GlobalData社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
Breo Ellipta(ぜんそく):市場の予測と分析 Breo Ellipta (Asthma) - Forecast and Market Analysis to 2023
出版日: 2014年08月31日 ページ情報: 英文 53 Pages
概要

Breo Ellipta(欧州ではRelvar Elliptaという名称で上市)は、フロ酸フルチカゾンとビランテロールトリフェニル酢酸塩のFDC(多剤混合薬)で、ICS(吸入用ステロイド薬)とLABA(長時間作用性β2刺激薬)の双方が必要なぜんそく患者の維持療法に用いられています。投薬には新しいDPI(乾燥粉末吸入器)装置であるElliptaを利用します。ぜんそくの維持療法向け医薬品としては初めて、1日1回の投与ですむようになりました。配合成分の1つであるフロ酸フルチカゾンは、潜在的な消炎効果のある合成三フッ化コルチコステロイドで、それが1日当たりの投与回数を1回にまで減らし、患者コンプライアンス・治療成績の改善につながっています。フロ酸フルチカゾンはまた、GSKによりスタンドアロン型のICS治療薬としても開発が進められています。

当レポートでは、ぜんそくの治療薬の一つ、Breo Elliptaの世界市場について分析し、ぜんそくの概要や治療法、競合する企業・薬品の概要、市場競争の概況、Breo Elliptaの商品情報(特色・効能・安全性など)、世界の主要国における市場販売額の見通し(今後10年間分)などを調査して、その結果を概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

  • 分析の背景事情
  • 関連報告
  • 公開予定の関連報告書

第3章 疾患の概要

  • 病因と病態生理学
    • 病因
    • 病態生理学
    • 予後
    • 生活の質(QoL)
  • 症状

第4章 疾患管理

  • 診断および治療概要
    • 診断
    • 治療ガイドライン、臨床診療および代表的な処方薬
    • 臨床診療

第5章 競合評価

  • 概要
  • 戦略的競合評価

第6章 Breo Ellipta(フロ酸フルチカゾン/ビランテロールトリフェニル酢酸塩)

  • 概要
  • 有効性
  • 安全性
  • SWOT分析
  • 予測

第7章 付録

図表一覧

目次

GlobalData has released its new PharmaPoint Drug Evaluation report, "Breo Ellipta (Asthma) - Forecast and Market Analysis to 2023". The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.

Breo Ellipta (or Relvar Ellipta in Europe) is an FDC of fluticasone furoate and vilanterol trifenatate for the maintenance treatment of asthma in patients who need both an ICS and a LABA. Breo is dosed via a new DPI device, Ellipta. Breo's pharmacodynamics allow for once-daily administration, and it is going to be the first FDC that allows for once-daily administration for the maintenance treatment of asthma. This is due to its ICS component, fluticasone furoate, which is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity that can be dosed once a day, thus improving patient compliance and treatment outcomes. Fluticasone furoate is also being developed by GSK as a stand-alone ICS therapy.

Scope

  • Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Breo Ellipta including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Breo Ellipta for the top eight countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Asthma
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Breo Ellipta performance
  • Obtain sales forecast for Breo Ellipta from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
    • 3.1.4. Quality of Life
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines, Clinical Practice, and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Breo Ellipta (fluticasone furoate/vilanterol trifenatate)

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety
  • 6.4. SWOT Analysis
  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed Asthma Patients
    • 7.4.2. Percent Drug-Treated Patients
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Individual Drug Assumptions
    • 7.4.5. Generic Erosion
  • 7.5. Physicians and Specialists Included in This Study
  • 7.6. About the Authors
    • 7.6.1. Author
    • 7.6.2. Author/Reviewer
    • 7.6.3. Reviewer
    • 7.6.4. Global Head of Healthcare
  • 7.7. About GlobalData
  • 7.8. Disclaimer

List of Tables

  • Table 1: Symptoms of Asthma
  • Table 2: Treatment Guidelines for Asthma by Country
  • Table 3: Most Prescribed Drugs for Asthma by Class and Disease Severity in the Global Markets, 2013
  • Table 4: Dosing of Common ICSs for Adult Asthma Therapy to Achieve Equivalent Therapeutic Potency
  • Table 5: Recommended Low Daily Dose of ICSs in Children with Asthma Under Five Years of Age
  • Table 6: Leading Treatments for Asthma, 2014
  • Table 7: Product Profile - Breo Ellipta
  • Table 8: Efficacy - Breo Ellipta Versus Flovent
  • Table 9: Safety - Breo Ellipta Versus Flovent
  • Table 10: Breo Ellipta SWOT Analysis, 2014
  • Table 11: Global Sales Forecast ($) for Breo Ellipta, 2013-2023
  • Table 12: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1:Stepwise Disease Management Approach for Asthma in Adults
  • Figure 2: Stepwise Disease Management Approach for Asthma in Children Age Five and Younger
Back to Top